Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.5B
164M shares
52-week range
$6.20 – $11.97
55% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.46%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $34.3M | $18.7M | $22.4M | $197.6M | $1.60B | $556.4M | $682.2M | $1.12B |
| Cost of revenue | $0 | $113.8M | $0 | $0 | $902.6M | $343.8M | $202.7M | $71.1M |
| Gross profit | $34.3M | −$95.2M | $22.4M | $197.6M | $696.3M | $212.6M | $479.4M | $1.05B |
| Gross margin | 100.0% | -510.0% | 100.0% | 100.0% | 43.5% | 38.2% | 70.3% | 93.7% |
| R&D | $173.8M | $113.8M | $747.0M | $2.53B | $1.24B | $737.5M | $391.2M | $336.8M |
| Operating income | −$173.9M | −$120.6M | −$416.7M | −$1.69B | −$644.7M | −$566.5M | −$248.9M | $563.3M |
| EBITDA | −$163.0M | −$113.3M | −$398.2M | −$1.68B | −$604.7M | −$487.4M | −$108.0M | $492.3M |
| Net income | −$184.7M | −$130.1M | −$418.3M | −$1.74B | −$657.9M | −$545.1M | −$187.5M | $440.3M |
| Net margin | -538.8% | -697.1% | -1868.2% | -882.5% | -41.1% | -98.0% | -27.5% | 39.2% |
| EPS (diluted) | -9.99 | -5.40 | -7.43 | -23.44 | -8.42 | -5.41 | -1.23 | 2.54 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $410M | $-0.47 | $-2.09–$1.29 | 8 |
| 2027 | $257M | $-0.27 | $-0.64–$0.01 | 7 |
| 2028 | $349M | $0.55 | $-0.38–$1.17 | 6 |
| 2029 | $405M | $0.85 | $0.49–$1.26 | 4 |
Forward consensus · source: Financial Modeling Prep
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
www.novavax.comNo one on the platform currently holds NVAX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 497,383 | $4.0M |
| Execution date | Ratio |
|---|---|
| 2019-05-10 | 1-for-20reverse |
No one on the platform has traded NVAX yet.
| $1.1B |
| — |
| PGENPrecigen, Inc. | $5.92 | +1.02% | $1.8B | — |
| TERNTerns Pharmaceuticals, Inc. | $52.95 | -0.03% | $4.8B | — |
Source: Financial Modeling Prep · peers by sector/industry
$NVAX sometimes I think no one has ever looked at the one year chart. The five year chart shows the death of the previous version of the company. The past year - lets call it "novavax 2.0" - is probably the beginning of a sustained uptrend as Sanofi royalties begin to book, Pfizer begins to hit milestones, and MTAs begin to convert to development agreements. I legit think y'all are looking at 300 percent gains in a couple years.
View on StockTwits ↗$NVAX The closing action on the SP was interesting, but if something leaked out, it wasn't leaked to a large audience. The volume didn't even reach current daily average volume. Early action tomorrow should be interesting.
View on StockTwits ↗$NVAX Brian Foard /Novavax The assumption that his "deep knowledge of Matrix-M" makes him the perfect guy to lead the deal actually works against him legally.At Sanofi, Foard sat on the Executive Committee when the Novavax deal was finalized in mid-2024. Because of this, Sanofi's legal team knows exactly what high-level projections, pricing structures, and long-term vaccine strategies Foard was exposed to before he left for Merck in 2026.If Merck puts Foard at the head of active contract negotiations with Novavax, it creates a massive target for Sanofi's lawyers . To keep the deal legally clean, Merck's separate business development teams must negotiate with Novavax independently. If the science is a match, and Business Development secures the contract, the deal gets handed to Foard.He isn't being bypassed because of a lack of talent or importance. He is being protected. Merck poached him from Sanofi because he is a legendary commercial builder. Merck wants his hands totally clean
View on StockTwits ↗$NVAX when is the last time we’ve seen any news after hours??? It’s been at least 3 years, holy shit before you know it I’ll be on the blue pill…
View on StockTwits ↗$NVAX Chowda just offered to take all my shares for $30. Should I take it?
View on StockTwits ↗$NVAX @Biotechlineup I did some searching and have a question on just what Brian Foard's role was in the Sanofi partnership. I can't find any direct evidence that he was the architect behind that deal. Please direct me to where this information is, thanks. I found he was EVP Specialty Care at Sanofi at the time of the deal. FWIW, AI says he wasn't involved in structuring the deal and lists 3 others that were, including Paul Hudson. Asking to verify my expectations around the latest BP who has signed an MTA with Novavax for 9 therapeutic areas....Merck is speculated on this, just digging into this further. Thanks.
View on StockTwits ↗$NVAX Now you know why Novavax never had a chance on its own. Never could get a foot hold. They are even going after Sanofi for basically telling the truth about how superior Nuvaxovid is!! It just is by far ! Just goes to show how hard they are pushing in Europe. Sanofi not Novavax. They rule over there.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Trading at 1.2× sales vs its 2.1× historical median P/S.
Fair value ≈ $15.81 · price $9.36 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.